Goserelin

Generic Name: Goserelin

Brand Names: Zoladex

Drug Type: Small Molecule

Chemical Formula: C_₅₉H_₈₄N_₁₈O_₁₄

CAS Number: 65807-02-5

Unique Ingredient Identifier: 0F65R8P09N

Background: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication: Goserelin is indicated for:

Associated Conditions: Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate

Associated Therapies: Palliative Treatment

Clinical Trials

Testosterone Effects on Men With the Metabolic Syndrome

Phase 2

Withdrawn

Conditions: Metabolic Syndrome

First Posted Date: 2006-09-28

Last Posted Date: 2008-12-05

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 72

Registration Number: NCT00382057

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Phase 3

Completed

Conditions: Early-stage Breast Cancer

Interventions: Drug: Cyclophosphamide
Drug: Goserelin
Drug: Tamoxifen
Drug: Methotrexate
Drug: Fluorouracil implant

First Posted Date: 2006-04-03

Last Posted Date: 2023-06-29

Lead Sponsor: Austrian Breast & Colorectal Cancer Study Group

Target Recruit Count: 1099

Registration Number: NCT00309478

Prostate Adenocarcinoma TransCutaneous Hormones

Phase 3

Conditions: Hot Flashes
Anemia
Osteoporosis
Prostate Cancer
Cardiovascular Complications

Interventions: Drug: Goserelin
Drug: Estradiol

First Posted Date: 2006-03-17

Last Posted Date: 2020-11-27

Lead Sponsor: University College, London

Target Recruit Count: 2200

Registration Number: NCT00303784

Locations: 🇬🇧
Walsgrave Hospital, Coventry, England, United Kingdom
🇬🇧
Mayday University Hospital, Croydon, England, United Kingdom
🇬🇧
Kidderminster Hospital, Kidderminster Worcestershire, England, United Kingdom

and more 29 locations

CMAB vs IMAB in Metastatic Prostate Cancer

Phase 4

Withdrawn

Conditions: Metastatic Prostate Cancer

First Posted Date: 2005-11-18

Last Posted Date: 2007-08-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 15

Registration Number: NCT00255268

Locations: 🇲🇽
Research Site, Mexico City, Mexico

Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-09-20

Last Posted Date: 2010-06-14

Lead Sponsor: German Breast Group

Target Recruit Count: 62

Registration Number: NCT00196846

Locations: 🇩🇪
Universitätsfrauenklinik, Rostock Universität, Rostock, Mecklenburg Vorpommern, Germany

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2018-06-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00165399

Locations: 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Stage III Prostate Cancer
Recurrent Prostate Carcinoma
Stage IIB Prostate Cancer
Stage IIA Prostate Cancer
Stage I Prostate Cancer

Interventions: Drug: Bicalutamide
Drug: Goserelin Acetate
Biological: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Biological: Recombinant Vaccinia-TRICOM Vaccine
Biological: Sargramostim

First Posted Date: 2005-04-19

Last Posted Date: 2015-06-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00108732

Locations: 🇺🇸
Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 4 locations

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-04-22

Last Posted Date: 2023-08-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 180

Registration Number: NCT00002889

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Radiation: radiation therapy
Drug: flutamide
Drug: Zoladex
Drug: Lupron

First Posted Date: 2004-02-27

Last Posted Date: 2018-06-14

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 2028

Registration Number: NCT00002597

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 236 locations

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: buserelin
Drug: flutamide
Drug: goserelin
Drug: leuprolide acetate
Drug: nilutamide
Procedure: orchiectomy
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2020-04-03

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 361

Registration Number: NCT00002633

Locations: 🇨🇦
QEII Health Sciences Center, Halifax, Nova Scotia, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy